{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:01:11Z","timestamp":1793548871690,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,3]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>An urban, multidisciplinary obesity community clinic in Vancouver, Canada, from November 2018 to April 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      483 adults with a body mass index (BMI) of \u226730\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      who had filled a new prescription for subcutaneous semaglutide or liraglutide, with at least 6-month follow-up, were included (mean follow-up: 17.3 months). Individuals with prior bariatric surgery were excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>The primary outcome was the %TBWL over a mean follow-up period of 520 days. Participant\u2019s TWBL was categorised as non-response (&lt;5%\u2009TBWL), moderate response (5%\u201315%\u2009TBWL) or hyper-response (&gt;15%\u2009TBWL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The average %TBWL in the cohort was 12.2%. Among the participants, 17.8% had a non-response, 48.4% had a moderate response and 33.8% had a hyper-response. In the multivariable regression analysis, being a woman was associated with hyper-response (adjusted OR 1.92, CI 1.01 to 3.65, p=0.048). Age, diabetes status, baseline BMI, being sedentary, anxiety and depression were not independently associated with TBWL in response to GLP-1 analogue therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world setting, female sex was found to be associated with a hyper-response to GLP-1 analogue therapy for obesity management. Other clinical factors evaluated, including diabetes status, were not associated with the response. Future research should assess additional variables and support the development of novel biomarkers that are associated with weight loss response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-089477","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:02:48Z","timestamp":1737000168000},"page":"e089477","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1350-175X","authenticated-orcid":false,"given":"Peter","family":"Squire","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Naude","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zentner","sequence":"additional","affiliation":[{"name":"Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Medicine, Revolution Medical Clinic, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Bittman","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Revolution Medical Clinic, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-6617","authenticated-orcid":false,"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Revolution Medical Clinic, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025121422150564000_15.1.e089477.1","unstructured":"World Obesity Atlas . World obesity federation. 2022. Available: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2022"},{"key":"2025121422150564000_15.1.e089477.2","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20210205"},{"key":"2025121422150564000_15.1.e089477.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.04.016"},{"key":"2025121422150564000_15.1.e089477.4","unstructured":"Alves A , Larocque A , Matson P , et al . Obesity trends and the impact on morbidity and mortality costs obesity trends and the impact on morbidity. 2021."},{"key":"2025121422150564000_15.1.e089477.5","doi-asserted-by":"crossref","DOI":"10.3390\/nu14112217","article-title":"The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials","volume":"14","author":"Alabduljabbar","year":"2022","journal-title":"Nutrients"},{"key":"2025121422150564000_15.1.e089477.6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00213-0"},{"key":"2025121422150564000_15.1.e089477.7","doi-asserted-by":"crossref","first-page":"108935","DOI":"10.1016\/j.diabres.2021.108935","article-title":"Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study","volume":"178","author":"Jensterle","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2025121422150564000_15.1.e089477.8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121422150564000_15.1.e089477.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"2025121422150564000_15.1.e089477.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"2025121422150564000_15.1.e089477.11","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2021.1831"},{"key":"2025121422150564000_15.1.e089477.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2025121422150564000_15.1.e089477.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.02.005"},{"key":"2025121422150564000_15.1.e089477.14","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"},{"key":"2025121422150564000_15.1.e089477.15","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202"},{"key":"2025121422150564000_15.1.e089477.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000704","article-title":"Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA","volume":"7","author":"Singhal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025121422150564000_15.1.e089477.17","article-title":"What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue","volume":"15","author":"Klair","year":"2023","journal-title":"Cureus"},{"key":"2025121422150564000_15.1.e089477.18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12325-017-0652-2","article-title":"Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study","volume":"35","author":"Lapolla","year":"2018","journal-title":"Adv Ther"},{"key":"2025121422150564000_15.1.e089477.19","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0258"},{"key":"2025121422150564000_15.1.e089477.20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.15277\/bjdvd.2015.046","article-title":"Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit","volume":"15","author":"Thong","year":"2015","journal-title":"Br J Diabetes"},{"key":"2025121422150564000_15.1.e089477.21","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12030454","article-title":"Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J Pers Med"},{"key":"2025121422150564000_15.1.e089477.22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.EJ16-0552","article-title":"Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan","volume":"64","author":"Onishi","year":"2017","journal-title":"Endocr J"},{"key":"2025121422150564000_15.1.e089477.23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/dom.13086","article-title":"Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c","volume":"20","author":"Gallwitz","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025121422150564000_15.1.e089477.24","first-page":"123","article-title":"Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience","volume":"6","author":"Anichini","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025121422150564000_15.1.e089477.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100387","article-title":"Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes","volume":"2","author":"Overgaard","year":"2021","journal-title":"Cell Rep Med"},{"key":"2025121422150564000_15.1.e089477.26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/cob.12128","article-title":"Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity","volume":"6","author":"Nathan","year":"2016","journal-title":"Clin Obes"},{"key":"2025121422150564000_15.1.e089477.27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02153-x"},{"key":"2025121422150564000_15.1.e089477.28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.12639","article-title":"Exposure-response analyses of liraglutide 3.0 mg for weight management","volume":"18","author":"Wilding","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2025121422150564000_15.1.e089477.29","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/dom.13358","article-title":"Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes","volume":"20","author":"Petri","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025121422150564000_15.1.e089477.30","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2021-0070","article-title":"Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes","volume":"8","author":"Mosikian","year":"2022","journal-title":"Fut Sci OA"},{"key":"2025121422150564000_15.1.e089477.31","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1365162","article-title":"Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity","volume":"2019","author":"Babenko","year":"2019","journal-title":"J Diabetes Res"},{"key":"2025121422150564000_15.1.e089477.32","doi-asserted-by":"crossref","first-page":"154388","DOI":"10.1016\/j.metabol.2020.154388","article-title":"Factors affecting weight loss variability in obesity","volume":"113","author":"Dent","year":"2020","journal-title":"Metab Clin Exp"},{"key":"2025121422150564000_15.1.e089477.33","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13148","article-title":"Predictors of successful weight loss outcomes amongst individuals with obesity undergoing lifestyle interventions: A systematic review","volume":"22","author":"Chopra","year":"2021","journal-title":"Obes Rev"},{"key":"2025121422150564000_15.1.e089477.34","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1751"},{"key":"2025121422150564000_15.1.e089477.35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2566"},{"key":"2025121422150564000_15.1.e089477.36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1874230001105010008","article-title":"Leptin in the General Population, Differences in Sex Hormones, Blood Lipids, Gender and Life Style Characteristics","volume":"5","author":"Olstad","year":"2011","journal-title":"TOBSJ"},{"key":"2025121422150564000_15.1.e089477.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2006.00270.x"},{"key":"2025121422150564000_15.1.e089477.38","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0200"},{"key":"2025121422150564000_15.1.e089477.39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000365975","article-title":"Role of the rs6923761 gene variant in glucagon-like peptide 1 receptor gene on cardiovascular risk factors and weight loss after biliopancreatic diversion surgery","volume":"65","author":"de Luis","year":"2014","journal-title":"Ann Nutr Metab"},{"key":"2025121422150564000_15.1.e089477.40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","article-title":"Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study","volume":"71","author":"Jensterle","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121422150564000_15.1.e089477.41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","article-title":"Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","volume":"11","author":"Dawed","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121422150564000_15.1.e089477.42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.814770","article-title":"Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-089477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:15:18Z","timestamp":1765779318000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-089477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-089477"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-089477","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}